| # | Title | Journal | Year | Citations |
|---|
| 1 | Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) | Lancet, The | 1998 | 3,216 |
| 2 | Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials | Lancet, The | 2014 | 1,971 |
| 3 | A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease | New England Journal of Medicine | 2008 | 1,969 |
| 4 | Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial | Lancet Oncology, The | 2014 | 1,740 |
| 5 | Structure of a nanobody-stabilized active state of the β2 adrenoceptor | Nature | 2011 | 1,523 |
| 6 | Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial | Lancet, The | 2008 | 1,442 |
| 7 | Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia | JAMA - Journal of the American Medical Association | 2015 | 1,166 |
| 8 | Sexual Problems and Distress in United States Women | Obstetrics and Gynecology | 2008 | 1,151 |
| 9 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial | Lancet Oncology, The | 2016 | 950 |
| 10 | Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trial | Journal of Thrombosis and Haemostasis | 2007 | 942 |
| 11 | Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial | Lancet, The | 2010 | 913 |
| 12 | Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | New England Journal of Medicine | 2017 | 858 |
| 13 | Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk | JAMA - Journal of the American Medical Association | 2019 | 830 |
| 14 | Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial | Lancet Oncology, The | 2014 | 823 |
| 15 | Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site | Nature Structural Biology | 2002 | 811 |
| 16 | Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 | Lancet Oncology, The | 2015 | 786 |
| 17 | Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase | Molecular Cell | 2007 | 770 |
| 18 | BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1 | Nature Immunology | 2003 | 768 |
| 19 | The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients | Journal of the American College of Cardiology | 2014 | 733 |
| 20 | The promise and peril of chemical probes | Nature Chemical Biology | 2015 | 698 |
| 21 | Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study | Lancet, The | 2004 | 665 |
| 22 | High-Turnover Palladium Catalysts in Cross-Coupling and Heck Chemistry: A Critical Overview | Advanced Synthesis and Catalysis | 2004 | 602 |
| 23 | A specific antidote for dabigatran: functional and structural characterization | Blood | 2013 | 541 |
| 24 | Hemorrhagic Transformation of Ischemic Brain Tissue | Stroke | 2001 | 508 |
| 25 | Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades | Free Radical Biology and Medicine | 2000 | 489 |
| 26 | Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial | European Heart Journal | 2011 | 487 |
| 27 | Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial | Lancet, The | 2003 | 476 |
| 28 | Recommendations on health-related quality of life research to support labeling and promotional claims in the United States | Quality of Life Research | 2000 | 460 |
| 29 | Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials | Lancet, The | 2018 | 457 |
| 30 | Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells | Nature | 2020 | 440 |
| 31 | Incorporating the Patient's Perspective into Drug Development and Communication: An Ad Hoc Task Force Report of the Patient-Reported Outcomes (PRO) Harmonization Group Meeting at the Food and Drug Administration, February 16, 2001 | Value in Health | 2003 | 431 |
| 32 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial | Annals of Oncology | 2017 | 425 |
| 33 | Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes | JAMA - Journal of the American Medical Association | 2019 | 423 |
| 34 | Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature | European Respiratory Review | 2012 | 421 |
| 35 | Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis | New England Journal of Medicine | 2017 | 413 |
| 36 | Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Lancet Oncology, The | 2012 | 390 |
| 37 | Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study) | American Journal of Cardiology | 2007 | 389 |
| 38 | Electronic health records to facilitate clinical research | Clinical Research in Cardiology | 2017 | 387 |
| 39 | Key Green Chemistry research areas from a pharmaceutical manufacturers’ perspective revisited | Green Chemistry | 2018 | 384 |
| 40 | Managing the challenge of chemically reactive metabolites in drug development | Nature Reviews Drug Discovery | 2011 | 382 |
| 41 | Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects | Clinical Pharmacokinetics | 2008 | 374 |
| 42 | Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II) | Thrombosis and Haemostasis | 2011 | 374 |
| 43 | Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities | Drug Metabolism and Disposition | 2012 | 373 |
| 44 | Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial | Lancet Diabetes and Endocrinology,the | 2013 | 371 |
| 45 | Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study | Lancet, The | 2017 | 364 |
| 46 | Impulse control disorders in parkinson disease: A multicenter case–control study | Annals of Neurology | 2011 | 361 |
| 47 | Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 1): an open-label, randomised phase 3 trial | Lancet Oncology, The | 2015 | 358 |
| 48 | Pyrazole Urea-Based Inhibitors of p38 MAP Kinase: From Lead Compound to Clinical Candidate | Journal of Medicinal Chemistry | 2002 | 346 |
| 49 | SGLT-2 inhibitors and cardiovascular risk: Proposed pathways and review of ongoing outcome trials | Diabetes and Vascular Disease Research | 2015 | 333 |
| 50 | Shared and distinct mechanisms of fibrosis | Nature Reviews Rheumatology | 2019 | 331 |
